Total Company Value: Denali Corp (DNLI)

Official company branding of denalitherapeutics.com (DNLI)

The price history of Denali Therapeutics (DNLI) shares on the GURU.Markets platform reflects the dynamics of a company developing treatments for CNS pathologies, where risks are tied to the high cost of research and the probability of clinical trial failure. The current Enterprise Value stands at 2410.68. The business relies on the support of industry behemoths while remaining independent of market fluctuations. A unique method of delivering substances to the brain will provide the issuer with exceptional pricing power over future products.

DNLI (Denali Corp) Total Company Value history from 11/23/2025 to 10/29/2026

Denali Therapeutics (DNLI) - metric breakdowns and financial figures

- price and consensus price forecast:
Share Price Denali|DNLI - Price Target Chart
- market capitalization data:
Market Value Denali Therapeutics|DNLI - Enterprise Value
- book capitalization data:
Net Assets per Share Denali Therapeutics|DNLI - Company Book Value|Capitalization to Book Value Ratio denalitherapeutics.com|DNLI - Company Total Assets
- debt and liquidity data:
Debt to Capital Denali Therapeutics|DNLI - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital denalitherapeutics.com|DNLI - Company Debts|Debt to Net Assets Ratio Denali Therapeutics|DNLI - Company Long-Term Debt|Short-Term Debt Denali Therapeutics
Comprehensive company analysis:Denali (DNLI)
Mass-produced product of Denali Therapeutics

Enterprise Value (EV) sums market capitalization and net debt, determining the total buyout price of a business adjusted for liquidity. The current value of 2410.68 in the operating value (EV) of Denali Therapeutics serves as a baseline for asset stress testing, reflecting the market valuation of the breakthrough neurotechnologies for which the scientific community trusts Denali Therapeutics to solve the most complex challenges of drug delivery to the brain.

Direct competitors

Biogen Inc - Business Value|NBIX - Total Company Value|RGC - Total Company Value|Axsome Therapeutics - Enterprise Value|ACAD (acadia-pharm.com) - Company Buyout Price|Total Company Value Xenon (XENE)|Business Value Viking Therapeutics Inc|Supernus Pharma - Enterprise Value|Total Enterprise Value Catalyst Corp CPRX|Real Price to Acquire Entire Company HRMY (Harmony Biosciences)|biohavenpharma.com - Enterprise Value|Total Company Value Amylyx Pharmaceuticals, Inc. (AMLX)|TRVI: Value Adjusted for Debt and Cash|Total Company Value PRAX|Anavex Life Sciences Corp (AVXL) - Total Enterprise Value|Enterprise Value CeriBell, Inc. (CBLL)|Business Value Prothena Corp|Alector, Inc. - Enterprise Value|Total Enterprise Value ANNX (Annexon Biosciences)|OMER - Total Company Value|Business Value Neurogene Therapeutics NGNE|AC Immune - Enterprise Value|VYGR: Enterprise Value|Neumora Therapeutics, Inc. (NMRA) - Total Company Value|Scilex Holding (SCLX) - Total Company Value|TVGN: Enterprise Value|Company Buyout Price Alpha Cognition Corp (ACOG)|Cognition Therapeutics, Inc. (CGTX) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash inhibikase.com IKT|Real Price to Acquire Entire Company Cassava Sciences (SAVA)|Aggregate Business Value Assertio Holdings ASRT|Enterprise Value Coya (COYA)|VTGN - Value Adjusted for Debt and Cash|Enterprise Value OVID|ABOS (acumenpharm.com) - Total Enterprise Value|CRVO - Total Company Value|Value Adjusted for Debt and Cash Alterity Therapeutics Ltd|Enterprise Value CLNN|Enterprise Value PEPG (pepgen.com)|Jupiter Neurosciences (JUNS) - Total Company Value|Full Business Value relmada.com RLMD|ANVS (Annovis Bio) - Enterprise Value|Grace Therapeutics, Inc. (GRCE) - Total Enterprise Value|AIFF: Real Price to Acquire Entire Company|Enterprise Value Klotho Neurosciences|NeuroSense Therapeutics Ltd (NRSN) - Real Price to Acquire Entire Company|Aggregate Business Value revivapharma.com|MTVA (MetaVia Inc) - Enterprise Value|Company Buyout Price NeurAxis Inc. (NRXS)|Helius Medical Technologies - Enterprise Value|Passage Bio Inc. - Real Price to Acquire Entire Company|Total Company Value NEUP (Neuphoria)|NERV - Company Buyout Price|Enterprise Value Athira Pharma|ADXN (Addex Therapeutics Ltd.) - Business Value|Total Company Value Alzamend Neuro Inc. (ALZN)|Business Value CYCN|Total Company Value Protagenic Therapeutics (PTIX)|Total Company Value pasitheaclinics.com (KTTA)|Enterprise Value CRGT|Avenue Therapeutics Inc. - Company Buyout Price|Brainstorm Cell Therapeutics, Inc. (BCLI) - Total Company Value|CARA - Business Value|Enterprise Value CHRO|Total Enterprise Value Eliem Therapeutics Inc.|ITCI (Intra-Cellular Therapies Inc.) - Real Price to Acquire Entire Company|Enterprise Value LBPH|Marinus (MRNS) - Total Company Value|Value Adjusted for Debt and Cash NKGN (NKGen Biotech Corp)|NRBO: Total Company Value|Total Enterprise Value sagerx.com SAGE|Synaptogenix (SNPX) - Enterprise Value|TRVN - Business Value|Enterprise Value VIGL|WENA (anewmeds.com) - Total Enterprise Value|Total Company Value Cerevel Therapeutics (CERE)